Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer.

Publication/Presentation Date

6-1-2020

Abstract

Background: The American Joint Committee on Cancer staging and other prognostic tools fail to account for stage-independent variability in outcome. We developed a prognostic classifier adding Immunoscore to clinicopathological and molecular features in patients with stage III colon cancer.

Methods: Patient (n = 559) data from the FOLFOX arm of adjuvant trial NCCTG N0147 were used to construct Cox models for predicting disease-free survival (DFS). Variables included age, sex, T stage, positive lymph nodes (+LNs), N stage, performance status, histologic grade, sidedness,

Results: Poorer DFS was found for tumors that were T4 vs T3 (hazard ratio [HR] = 1.76, 95% confidence interval [CI] = 1.19 to 2.60;

Conclusions: The Immunoscore can enhance the accuracy of survival prediction among patients with stage III colon cancer.

Volume

4

Issue

3

First Page

023

Last Page

023

ISSN

2515-5091

Disciplines

Medicine and Health Sciences | Oncology

PubMedID

32455336

Peer Reviewed for front end display

Peer-Reviewed

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Department of Medicine Faculty

Document Type

Article

Share

COinS